Jump to content

US watching upcoming changes to Canadian drug prices - sees reforms as potential threats to U.S. intellectual property rights

Recommended Posts




The United States is keeping Canada on its "watch list" of countries where policies and practices could pose a threat to American intellectual property rights.


In its annual report on foreign perils to American rights holders, the Office of the United States Trade Representative (USTR) raised concerns about Canada's plan to recalibrate how it calculates the price of prescription drugs.


Why, you ask?



The federal Liberal government announced last summer that the arm's-length Patented Medicine Prices Review Board would stop using drug prices in the U.S. and Switzerland — among the highest in the world — to help it determine what Canadian patients should pay.


In other words, the Trudeau government has decided that using US prices in calculations to determine a fair-market price is not valid since US drug prices are massively inflated.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Recently Browsing   0 members

    • No registered users viewing this page.
  • Create New...